ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0084

Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review

Silke Neusser1, Anja Neumann1, Christian Speckemeier1, Pauline zur NIeden1, Sarah Schlierenkamp1, Anke Walendzik1, Ute Karbach2, Ioana Andreica3, Kristina Vaupel4, Xenofon Baraliakos5 and Uta Kiltz4, 1Essener Forschungsinstitut für Medizinmanagement, Essen, Germany, 2Institute of Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), Cologne, Germany, 3Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Rheumazentrum Ruhrgebiet Herne, Herne, Germany

Meeting: ACR Convergence 2022

Keywords: autoimmune diseases, health behaviors, prevention, Qualitative Research, risk assessment

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with chronic inflammatory rheumatic diseases (CIRD) remain underrepresented in receiving vaccinations despite being disproportionately affected by infectious complications. The aim of our study was to systematically review the literature regarding vaccination willingness and vaccination hesitancy in CIRD patients with focus on the perspective of patients and physicians. .

Methods: A scoping review was conducted in PUBMED, EMBASE and the Cochrane Library through 2021. Study selection was performed by two independent reviewers, data were extracted using a standardized form and risk of bias was assessed using instruments from the McMaster University. Identified barriers and hurdles were synthesized by categorizing them into the WHO’s Measuring Behavioural and Social Drivers of Vaccination (BeSD) conceptual model.

Results: The search yielded 1,644 hits of which 30 publications were included (cross-sectional studies based on interviews (n=27) and intervention studies (n=3)) (Figure 1). The majority of studies reported barriers to influenza and pneumococcal vaccination only (n=9) or in combination with another vaccination (n=8) from the patients` perspective. Only one study assessed the view of rheumatologists. Patients mainly mentioned behavioral and social factors that negatively influenced their willingness to be vaccinated (Table 1 and Figure 2) while physicians saw organizational deficits as major barriers. Coverage of domains matched to the BeSD model suggests a lack of awareness of infection risk by both patients and physicians.

Conclusion: The view of vaccination in CIRD patients diverges between patients and rheumatologists. Our results show that in-depth counseling on vaccines is important for patients, whereas physicians need support in implementing specific immunization recommendations. The themes identified provide a starting point for future interventions to improve vaccine rates in CIRD patients.

Supporting image 1

Figure 1: Study selection flow chart

Supporting image 2

Table 1: Patients point of view

Supporting image 3

Figure 2: Allocation of identified categories to the domains of BeSD concept model


Disclosures: S. Neusser, None; A. Neumann, None; C. Speckemeier, None; P. zur NIeden, None; S. Schlierenkamp, None; A. Walendzik, None; U. Karbach, None; I. Andreica, None; K. Vaupel, None; X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi; U. Kiltz, AbbVie, Amgen, Biogen, Fresenius, GSK, Hexal, Novartis, Pfizer, Biocad, Lilly, Grünenthal, Janssen, MSD, Roche, UCB.

To cite this abstract in AMA style:

Neusser S, Neumann A, Speckemeier C, zur NIeden P, Schlierenkamp S, Walendzik A, Karbach U, Andreica I, Vaupel K, Baraliakos X, Kiltz U. Facilitators and Barriers of Vaccine Uptake in Patients with Chronic Inflammatory Rheumatic Disease: A Scoping Review [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/facilitators-and-barriers-of-vaccine-uptake-in-patients-with-chronic-inflammatory-rheumatic-disease-a-scoping-review/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/facilitators-and-barriers-of-vaccine-uptake-in-patients-with-chronic-inflammatory-rheumatic-disease-a-scoping-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology